Frontier Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Frontier Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-66,282	Closed	-$7.11M	–	276
2023 Q1	$7.11M	Sell	66,282 -72,020	-52%	-$8.29M	0.07%	212
2022 Q4	$15.2M	Buy	+138,302	New	+$8.97M	0.17%	175

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Frontier Capital Management's RXDX Position: Q2 2023 in Review

Frontier Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 66,282 shares — an estimated $7.11M sold.

Frontier Capital Management first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $15.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Frontier Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Frontier Capital Management sold 66,282 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $7.11M.
Frontier Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Frontier Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $15.2M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Frontier Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.